Streamlining Ultomiris Prior Authorization for Endocrinology

The Dual Challenge: Managing Ultomiris and Core Endocrinology PAs

Ultomiris is a high-volume prior authorization target across commercial, Medicare Advantage, and Medicaid managed care plans, requiring meticulous documentation and follow-up. Within endocrinology, this workload is amplified by a consistent demand for prior authorizations for critical diabetes and metabolic therapies. Practices must efficiently manage both specific high-PA drugs and the broad categories of endocrine treatments to maintain patient access and optimize revenue cycles.

Common Prior Authorization Triggers in Endocrinology

• GLP-1 receptor agonists (e.g., semaglutide, liraglutide, dulaglutide) for T2D and obesity indications.
• Dual GIP/GLP-1 agonists (e.g., tirzepatide) requiring specific diagnostic and step therapy criteria.
• Continuous Glucose Monitoring (CGM) systems (e.g., Dexcom G7, FreeStyle Libre 3/2) with varying coverage for T1D vs. T2D.
• Insulin pumps and tubeless systems (e.g., Tandem t:slim X2, Omnipod 5) often requiring prior MDI trials.
• SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) for T2D, heart failure, and CKD indications.
• Growth hormone therapy (e.g., somatropin biosimilars) requiring specific diagnostic documentation.

Streamlining Documentation for Complex Endocrinology Cases

Endocrinology prior authorizations frequently reference clinical guidelines such as the ADA Standards of Care, AACE Clinical Practice Guidelines, and ATA Guidelines. For drugs like Ultomiris and other endocrine therapies, payers often require specific data points including A1c levels, BMI, eGFR thresholds, prior medication trials, and detailed diagnostic documentation. Klivira's platform automates the aggregation of this clinical evidence directly from your EMR, ensuring comprehensive and compliant submissions.

Addressing Frequent Denial Reasons in Endocrinology

• Payer coverage gaps for obesity indications of GLP-1 RAs, or restrictive BMI criteria.
• Non-compliance with step therapy protocols for GLP-1 RAs, SGLT2 inhibitors, or insulin products.
• Lack of documented insulin-requiring status for T2D patients seeking CGM coverage.
• Insufficient documentation of prior MDI trials or patient adherence for insulin pump approval.
• Biosimilar substitution requirements not met for insulin or growth hormone therapies.

Klivira's Solution for Endocrinology Prior Authorization

Klivira's platform provides a robust solution for managing the high volume of prior authorizations in endocrinology, including complex cases like Ultomiris. We leverage EMR integration to pull necessary clinical data, apply ADA/AACE-guideline-aware step-therapy logic, and provide indication-specific routing for GLP-1s (T2D vs. obesity). Our system streamlines CGM and insulin pump re-authorization workflows with adherence documentation and tracks payer-specific obesity benefit status, reducing administrative burden and accelerating patient access to vital treatments.